SRPT - Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
2024-03-13 08:00:00 ET
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystrophy (DMD), the condition that's Sarepta's focus.
Does an upcoming new player on the scene pose a big-enough threat to Sarepta to justify selling the stock today? The answer is a bit more complicated than merely "no," so let's dive in and clarify the issue.
Regenxbio's gene therapy program is called RGX-202, and it could provide a measure of long-lasting relief to patients with DMD. The concept of RGX-202, as well as Sarepta's Elevidys therapy, is to replace the dysfunctional copies of a patient's disease-related genes with synthetically designed functional versions, such that when those genes are expressed by cells, the correct protein is produced rather than a dysfunctional version. Then the patient's symptoms, like muscle weakness and mobility issues, hopefully start to abate.
For further details see:
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?